NEW YORK (GenomeWeb News) — Molecular Diagnostics company SensiGen has received a $300,000 investment from Delaware Crossing Investor Group, a mid-Atlantic-based group of angel investors.
 
SensiGen, based in Ann Arbor, Mich., said it plans to use the funds to develop and sell its AttoSense molecular diagnostic technology, which blends PCR and mass spectrometry to locate biomarkers.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.